Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

418463

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hidradenitis Suppurativa
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps NHS England takes to assess the health and social care needs of patients with hidradenitis suppurativa; and what assessment he has made of the ability of the NHS to deliver efficient diagnosis and access to specialist care for such patients.
	tabling member constituency	West Lancashire
	tabling member printed	Rosie Cooper
	uin	10010
	answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England works in partnership with local commissioners and providers to ensure people with long-term conditions, such as hidradenitis suppurativa (HS), are supported to live healthily and independently and are empowered to take better control over the care they receive.</p><p> </p><p> </p><p> </p><p>The majority of patients with HS can be managed through routine access to primary and secondary care, including dermatology clinics, which is responsibility of the local National Health Service commissioners. Treatment and management of the condition involves antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe.</p><p> </p><p> </p><p> </p><p>For those patients with the more serious forms of HS, referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions, including HS, and has set out what providers must have in place in order to offer specialist dermatology care. This supports equity of access to a high quality service for patients wherever they live. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found by viewing the specialised dermatology service specification at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 10011 question first answered 16/09/2015 11:46:53 answering member 3918 label Biography information for Jane Ellison
	tabling member	1538 label Biography information for Rosie Cooper

418464

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hidradenitis Suppurativa
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what progress has been made by NHS England on the production of a commissioning policy for treatments associated with hidradenitis suppurativa; what the proposed scope of that policy is; and when he expects that policy to have been fully developed.
	tabling member constituency	West Lancashire
	tabling member printed	Rosie Cooper
	uin	10011
	answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England works in partnership with local commissioners and providers to ensure people with long-term conditions, such as hidradenitis suppurativa (HS), are supported to live healthily and independently and are empowered to take better control over the care they receive.</p><p> </p><p> </p><p> </p><p>The majority of patients with HS can be managed through routine access to primary and secondary care, including dermatology clinics, which is responsibility of the local National Health Service commissioners. Treatment and management of the condition involves antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe.</p><p> </p><p> </p><p> </p><p>For those patients with the more serious forms of HS, referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions, including HS, and has set out what providers must have in place in order to offer specialist dermatology care. This supports equity of access to a high quality service for patients wherever they live. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found by viewing the specialised dermatology service specification at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 10010 question first answered 16/09/2015 11:46:53 answering member 3918 label Biography information for Jane Ellison
	tabling member	1538 label Biography information for Rosie Cooper

418446

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Eyesight: Testing
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many people were diagnosed with (a) a brain tumour and (b) other conditions as a result of symptoms noticed during examinations by opticians in the last 12 months.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	10017
	answer	answer is ministerial correction date of answer 17/09/2015 answer text <p>Information provided by the Health and Social Care Information Centre shows that during 2013/14 there were 159,626 referrals from optometrists to secondary care. It is not possible, however, to identify a diagnosis given the collection of this information is not mandatory.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 17/09/2015 10:07:37 answering member 1201 label Biography information for Alistair Burt
	tabling member	4131 label Biography information for Jim Shannon

418447

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Statins
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will take steps to ensure patients prescribed statins can make a choice on what type of statins they receive.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	10020
	answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Decisions regarding the appropriateness of a particular treatment, including statins, should be made by clinicians in partnership with patients. The individual circumstances of each patient should be taken into account, alongside their medical history, needs and preferences.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/09/2015 10:04:02 answering member 3918 label Biography information for Jane Ellison
	tabling member	4131 label Biography information for Jim Shannon

418450

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Dementia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what criteria NICE has set for new dementia treatments to be recommended for provision by the NHS.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	10022
	answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The National Institute for Health and Care Excellence assesses significant new drugs and treatments, including those for the treatment of dementia, through its technology appraisal programme. Technology appraisals are conducted in accordance with NICE’s <em>Guide to the methods of technology appraisal 2013</em> which is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/article/pmg9/chapter/Foreword" target="_blank">www.nice.org.uk/article/pmg9/chapter/Foreword</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:15:57 answering member 4020 label Biography information for George Freeman
	tabling member	4131 label Biography information for Jim Shannon

418449

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Alzheimer's Disease: Dental Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will commission a study to investigate potential links between dental treatment and Alzheimer's disease.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	10023
	answer	answer is ministerial correction date of answer 17/09/2015 answer text <p>The Department has no plans to commission a study on the specific risk of transmission of Alzheimer’s disease in dentistry. There is no evidence that Alzheimer's disease can be transmitted through any medical procedure. In dentistry, patients are protected from the risk of infection by either mandatory single use instruments, or where instruments are reused, by guidance on strict decontamination procedures as per the Health Technical Memorandum 01-05: Decontamination in primary care dental practices - 2013 edition.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 17/09/2015 16:09:59 answering member 1201 label Biography information for Alistair Burt
	tabling member	4131 label Biography information for Jim Shannon

418451

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the implications for his policies of the decision by NHS England announced on 4 September 2015 to remove (a) the pancreatic cancer drug Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	10091
	answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>No such assessment has been made. We remain committed to continuing to invest in the Cancer Drugs Fund which has so far benefitted over 72,000 people with cancer in England.</p><p> </p><p> </p><p> </p><p>We understand that NHS England continues to work with manufacturers seeking to maintain drug and indication combinations within the Fund.</p><p> </p><p><strong> </strong></p><p> </p><p>NHS England has confirmed that patients who are already receiving a drug/indication which is to be removed from the Fund will continue to be treated with that drug until they and their clinicians consider it appropriate to discontinue treatment. In addition, drugs removed from the Fund will continue to be available via Individual Funding Requests if the individual patient meets clinical exceptionality criteria.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:22:40 answering member 4020 label Biography information for George Freeman
	tabling member	4056 label Biography information for Nic Dakin

418452

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what mechanisms there are for appeal against NHS England's decision announced on 4 September 2015 to remove (a) Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs; and if he will make a statement.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	10092
	answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England has advised that the mechanisms for appeal are as set out in Appendix G, section 11 of the Cancer Drugs Fund Standard Operating Procedures which are published on NHS England’s website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop-2015-16.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop-2015-16.pdf</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:23:43 answering member 4020 label Biography information for George Freeman
	tabling member	4056 label Biography information for Nic Dakin

418453

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the effect on cancer clinical trials of NHS England's decision announced on 4 September 2015 to remove (a) Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs; and if he will make a statement.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	10093
	answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>Neither the Department nor NHS England has made any such assessment.</p><p> </p><p> </p><p> </p><p>Advances in medical science means that new cancer medicines are emerging all the time and NHS England needs to regularly prioritise its national Cancer Drugs Fund (CDF) list so people can access these too. Decisions on which treatments are included on the list are made by the CDF expert clinical panel because it is right these decisions are clinically led.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:25:30 answering member 4020 label Biography information for George Freeman
	tabling member	4056 label Biography information for Nic Dakin

418712

	registered interest
	date	14/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent assessment his Department has made of the trends in the prevalence of diabetes; and if he will make a statement.
	tabling member constituency	Coventry South
	tabling member printed	Mr Jim Cunningham
	uin	10120
	answer	answer is ministerial correction date of answer 17/09/2015 answer text <p>Diagnosed diabetes prevalence is taken from the Quality and Outcomes Framework (QOF) and represents all patients who have been diagnosed with diabetes and included on GP registers.</p><p> </p><p> </p><p> </p><p>Diabetes prevalence is increasing. Diagnosed diabetes prevalence has increased from 2.3 million (5.3%) in 2009/10 to 2.8 million (6.2%) in 2013/14; an increase of nearly half a million people.</p><p> </p><p> </p><p> </p><p>Public Health England’s diabetes prevalence model estimates total diabetes prevalence for England and for all local authorities and clinical commissioning groups (CCG) in England. The model reflects the prevalence of diabetes (diagnosed and undiagnosed) and adjusts for the age, sex, ethnic group and deprivation pattern of the local population.</p><p> </p><p> </p><p> </p><p>The estimated total diabetes prevalence using the diabetes prevalence model is 7.5% in 2014.</p><p> </p><p> </p><p> </p><p>If current trends continue then we estimate that by 2030 there will be over 4 million people with diabetes. This represents 8.8% of the population aged 16 years and over.</p><p> </p><p> </p><p> </p><p>This data is publically available on the Healthier Lives website at:</p><p> </p><p> </p><p> </p><p><a href="http://healthierlives.phe.org.uk/topic/diabetes" target="_blank">http://healthierlives.phe.org.uk/topic/diabetes</a></p><p> </p><p> </p><p> </p><p>The website also provides diagnosed prevalence at the CCG level.</p><p> </p><p> </p><p> </p><p>Tackling diabetes is of great concern to this Government. Building on the National Diabetes Prevention Programme, the Department is developing its plans to improve outcomes for those at risk of and with diabetes. These will be announced in due course.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 10181 question first answered 17/09/2015 15:53:59 answering member 3918 label Biography information for Jane Ellison
	tabling member	308 label Biography information for Mr Jim Cunningham